Zynerba Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ZYN002 - transdermal gel · Epilepsy
  ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system.

Phase 2 pipeline

• ZYN002 - Cannabidiol Transdermal Gel

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zynerba Pharmaceuticals, Inc. portfolio CI brief
• Zynerba Pharmaceuticals, Inc. pipeline updates RSS